RecruitingPhase 1NCT06105151
Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
Studying Cap myopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vigonvita Life Sciences
- Principal Investigator
- Gang WangBeijing Anding Hospital of Capital Medical University
- Intervention
- VV119(SAD)(drug)
- Enrollment
- 82 target
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Beijing Anding Hospital of Capital Medical University, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06105151 on ClinicalTrials.govOther trials for Cap myopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07325344Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility StudyShandong University
- RECRUITINGNANCT07359287Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary CareUniversity Hospital, Caen
- ACTIVE NOT RECRUITINGNANCT07151261Ashwagandha for Nighttime WakingNational University of Natural Medicine
- RECRUITINGNANCT07268365Is Cap Assisted Endoscopy Useful in Acute Upper Gastrointestinal Bleeding ?Centre Hospitalier Universitaire, Amiens
- RECRUITINGPHASE2, PHASE3NCT07086313A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDOtsuka Pharmaceutical Co., Ltd.
- RECRUITINGPHASE4NCT07193277Butylphthalide for Cognitive Impairment in Elderly Patients With Focal EpilepsyFirst Affiliated Hospital of Wenzhou Medical University
- ACTIVE NOT RECRUITINGNCT06733337A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.Pfizer
- RECRUITINGPHASE3NCT06926829A Long-term Trial of EB-1020 in Adult Patients With ADHDOtsuka Pharmaceutical Co., Ltd.